Cowen Expands Biotechnology Equity Research Team with Addition of Chris Shibutani, MD

NEW YORK–(BUSINESS WIRE)–Oct. 5, 2015–
Cowen Group, Inc. (“Cowen”) (NASDAQ:COWN) today announced that Chris
Shibutani, MD has joined Cowen and Company’s equity research department
as a Managing Director to cover biotechnology stocks. Dr. Shibutani is
based in Boston and reports to Robert Fagin, Cowen’s Director of
Research.

“We are thrilled to welcome Dr. Shibutani to Cowen,” said Mr. Fagin.
“His incredible scholarship and breadth and depth of investment
experience make him a perfect fit with our world-class health care
effort.”

Dr. Shibutani began his Wall Street career at Hambrecht & Quist (later
JP Morgan), where he covered a variety of health care sectors, including
medical devices, life science tools, biotechnology and major
pharmaceuticals over a nearly 10-year period. He served as JP Morgan’s
global sector coordinator for major pharmaceuticals for three years. Dr.
Shibutani also has eight years of buyside investing experience, having
served in health care analyst and portfolio manager roles at UBS Global
Asset Management and Pioneer Investment Management. He was also a
consultant at Druganalyst Ltd.

Dr. Shibutani holds a BA, cum laude, in biology from Harvard University,
an MD from Columbia College of Physicians and Surgeons, and an MBA from
Columbia Business School. He was a medical intern in the Department of
Internal Medicine at Columbia Presbyterian Medical Center, and was
Resident and Clinical Fellow in Massachusetts General Hospital’s
Department of Anesthesiology and Critical Care. Dr. Shibutani was later
on the Clinical Faculty of the Department of Anesthesiology and Critical
Care at Memorial Sloan-Kettering Cancer Center.

About Cowen Group, Inc.

Cowen Group, Inc. is a diversified financial services firm and, together
with its consolidated subsidiaries, provides alternative asset
management, investment banking, research, and sales and trading services
through its two business segments: Ramius and its affiliates make up the
Company’s alternative investment segment, while Cowen and Company and
its affiliates make up the Company’s broker-dealer segment. Ramius
provides alternative asset management solutions to a global client base
and manages a significant portion of Cowen’s proprietary capital. Cowen
and Company and its affiliates offer industry focused investment banking
for growth-oriented companies, domain knowledge-driven research, a sales
and trading platform for institutional investors and a comprehensive
suite of prime brokerage services. Founded in 1918, the firm is
headquartered in New York and has offices worldwide.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151005005360/en/

Source: Cowen Group, Inc.

Sard Verbinnen & Co
Dan Gagnier / Carissa Felger, 212-687-8080